Evidence map›Paper›PMID 30675316›Full record

ArticleOncology letters2019

Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.

Hongbin Liu, Yunshan Hu, Rafael Rimoldi, Chloe Von Hagt, Edmund W C Khong, Nora Lee, Shaun Flemming, Andrew Spencer, Anthony E Dear

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Hongbin LiuDepartment of Medicine, Eastern Health Clinical School, Monash University, Melbourne, Victoria 3128, Australia.
Yunshan HuDepartment of Medicine, Eastern Health Clinical School, Monash University, Melbourne, Victoria 3128, Australia.
Rafael RimoldiDepartment of Medicine, Eastern Health Clinical School, Monash University, Melbourne, Victoria 3128, Australia.
Chloe Von HagtDepartment of Medicine, Eastern Health Clinical School, Monash University, Melbourne, Victoria 3128, Australia.
Edmund W C KhongDepartment of Medicine, Eastern Health Clinical School, Monash University, Melbourne, Victoria 3128, Australia.
Nora LeeDepartment of Haematology, Eastern Health Clinical School, Box Hill Hospital, Melbourne, Victoria 3128, Australia.
Shaun FlemmingAustralian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia.
Andrew SpencerAustralian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia.
Anthony E DearDepartment of Medicine, Eastern Health Clinical School, Monash University, Melbourne, Victoria 3128, Australia.
Eastern Health · AUMonash University · AUBox Hill Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent evidence suggests an association exists between resistance to epigenetic therapy (EGT) and the expression of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) in myeloid malignancies. Biomarkers are required to predict resistance to EGT in myeloid malignancies, which together with the delineation of associated molecular mechanisms, may provide additional understanding for novel treatment strategies when investigating resistance to EGT. The present study aimed to investigate the

Indexed as

biomarkerepigeneticmyelodysplasiamyeloid leukemiaprogrammed cell death protein 1

Identifiers

PMID30675316
PMCPMC6341830
OpenAlexW2904278469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.